Get started
Eli Lilly and CompanyEli Lilly and CompanyEli Lilly and Company

Eli Lilly and Company

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsForecastsSeasonalsBondsETFs

Chart


Full chart

Key facts today


Eli Lilly's Zepbound achieved $3.6 billion in sales for the third quarter, reflecting a 185% year-over-year increase, while Mounjaro generated $6.5 billion in sales during the same period.
A study showed Eli Lilly's blood thinner Effient outperformed AstraZeneca's Brilinta in diabetic patients undergoing artery-clearing procedures, with a 14.2% adverse event rate versus 16.6%.
Eli Lilly's obesity drug candidate, eloralintide, achieved significant weight loss of up to 20.1% in a recent mid-stage study and is set to enter late-stage trials next month.
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪767.85 B‬ CHF
Dividend yield (indicated)
0.59%
Price to earnings Ratio (TTM)
35
Basic EPS (TTM)
15 CHF
Net income (FY)
‪9.62 B‬ CHF
Revenue (FY)
‪40.91 B‬ CHF
Shares float
‪849.49 M‬
Beta (1Y)
0.57

Employees


Employees (FY)
‪47 K‬
Change (1Y)
‪+4 K‬ +9.30%
Revenue / Employee (1Y)
—
Net income / Employee (1Y)
—

About Eli Lilly and Company


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David A. Ricks
Website
lilly.com
Headquarters
Indianapolis
Founded
1876
ISIN
US5324571083
FIGI
BBG00Z4HJVR2
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Check out other big names from the same industry as LLYZ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


XS238628644
Eli Lilly and Company 1.625% 14-SEP-2043
Yield to maturity
5.71%
Maturity date
Sep 14, 2043
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044
Yield to maturity
5.65%
Maturity date
Jun 15, 2044
US532457BU1
Eli Lilly and Company 4.15% 15-MAR-2059
Yield to maturity
5.52%
Maturity date
Mar 15, 2059
LLY6153503
Eli Lilly and Company 5.65% 15-OCT-2065
Yield to maturity
5.50%
Maturity date
Oct 15, 2065
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064
Yield to maturity
5.49%
Maturity date
Aug 14, 2064
LLY6003397
Eli Lilly and Company 5.6% 12-FEB-2065
Yield to maturity
5.47%
Maturity date
Feb 12, 2065
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063
Yield to maturity
5.46%
Maturity date
Feb 27, 2063
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064
Yield to maturity
5.44%
Maturity date
Feb 9, 2064
US532457BT4
Eli Lilly and Company 3.95% 15-MAR-2049
Yield to maturity
5.43%
Maturity date
Mar 15, 2049
LLY6153502
Eli Lilly and Company 5.55% 15-OCT-2055
Yield to maturity
5.42%
Maturity date
Oct 15, 2055
US532457BY3
Eli Lilly and Company 2.25% 15-MAY-2050
Yield to maturity
5.41%
Maturity date
May 15, 2050

See all LLYZ bonds 

ETFs


VTI
Vanguard Total Stock Market ETF
Weight
1.01%
Market value
‪20.45 B‬
USD
VOO
Vanguard S&P 500 ETF
Weight
1.06%
Market value
‪14.95 B‬
USD
IVV
iShares Core S&P 500 ETF
Weight
1.41%
Market value
‪10.06 B‬
USD
SPY
SPDR S&P 500 ETF
Weight
1.41%
Market value
‪9.77 B‬
USD
SPY
SPDR S&P 500 ETF Trust
Weight
1.41%
Market value
‪9.77 B‬
USD
VUG
Vanguard Growth ETF
Weight
1.99%
Market value
‪6.80 B‬
USD
XLV
Health Care Select Sector SPDR Fund
Weight
14.67%
Market value
‪5.72 B‬
USD
VIG
Vanguard Dividend Appreciation ETF
Weight
2.82%
Market value
‪3.26 B‬
USD
IWF
iShares Russell 1000 Growth ETF
Weight
2.62%
Market value
‪3.21 B‬
USD
QUAL
iShares MSCI USA Quality Factor ETF
Weight
4.47%
Market value
‪2.33 B‬
USD
GSPX
iShares Core S&P 500 UCITS ETF
Weight
1.41%
Market value
‪1.94 B‬
USD

Explore more ETFs 

Sparks


Curated watchlists where LLYZ is featured.

See all sparks 

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on TURQUOISE exchange Eli Lilly and Company stocks are traded under the ticker LLYZ.
We've gathered analysts' opinions on Eli Lilly and Company future price: according to them, LLYZ price has a max estimate of 1,189.63 CHF and a min estimate of 614.64 CHF. Watch LLYZ chart and read a more detailed Eli Lilly and Company stock forecast: see what analysts think of Eli Lilly and Company and suggest that you do with its stocks.
LLYZ reached its all-time high on Mar 1, 2024 with the price of 705 CHF, and its all-time low was 200 CHF and was reached on Jun 7, 2021. View more price dynamics on LLYZ chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Eli Lilly and Company financials in yearly and quarterly reports right on TradingView.
Eli Lilly and Company is going to release the next earnings report on Feb 11, 2026. Keep track of upcoming events with our Earnings Calendar.
LLYZ earnings for the last quarter are 5.59 CHF per share, whereas the estimation was 4.53 CHF resulting in a 23.33% surprise. The estimated earnings for the next quarter are 5.61 CHF per share. See more details about Eli Lilly and Company earnings.
Eli Lilly and Company revenue for the last quarter amounts to ‪14.02 B‬ CHF, despite the estimated figure of ‪12.79 B‬ CHF. In the next quarter, revenue is expected to reach ‪13.94 B‬ CHF.
LLYZ net income for the last quarter is ‪4.45 B‬ CHF, while the quarter before that showed ‪4.49 B‬ CHF of net income which accounts for −0.99% change. Track more Eli Lilly and Company financial stats to get the full picture.
Yes, LLYZ dividends are paid quarterly. The last dividend per share was 1.19 CHF. As of today, Dividend Yield (TTM)% is 0.57%. Tracking Eli Lilly and Company dividends might help you take more informed decisions.
Eli Lilly and Company dividend yield was 0.67% in 2024, and payout ratio reached 44.39%. The year before the numbers were 0.78% and 77.91% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 14, 2025, the company has ‪47 K‬ employees. See our rating of the largest employees — is Eli Lilly and Company on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Eli Lilly and Company EBITDA is ‪22.53 B‬ CHF, and current EBITDA margin is 41.75%. See more stats in Eli Lilly and Company financial statements.
Like other stocks, LLYZ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eli Lilly and Company stock right from TradingView charts — choose your broker and connect to your account.